Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member

GlobeNewswire August 8, 2019

INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer

GlobeNewswire August 5, 2019

INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute's 7th Annual Immuno-Oncology Summit

GlobeNewswire August 1, 2019

INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019

GlobeNewswire July 25, 2019

INmune Bio Co-Founder and CEO Presents at Maxim Group's Conference on Alzheimer's Disease

GlobeNewswire July 3, 2019

INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE

GlobeNewswire June 27, 2019

INmune Bio Inc. Featured in Exclusive NetworkNewsWire Broadcast

GlobeNewswire June 11, 2019

INmune Bio to present Alzheimer's Drug Candidate XPro1595 at The TNF Conference

GlobeNewswire June 4, 2019

INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th

GlobeNewswire May 28, 2019

INmune Bio Announces Common Stock Purchase Agreement for up to $20.0 Million with Lincoln Park Capital

GlobeNewswire May 16, 2019

INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update

GlobeNewswire May 15, 2019

INmune Bio Closes Private Placement of Approximately $4.1 Million of Common Stock, Led by Insiders and Existing Shareholders

GlobeNewswire May 7, 2019

INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit

GlobeNewswire April 17, 2019